Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group

Fenner, Martin; Oing, Christoph; Dieing, Annette; Gauler, Thomas; Oechsle, Karin; Lorch, Anja; Hentrich, Marcus; Kopp, Hans-Georg; Bokemeyer, Carsten; Honecker, Friedemann

dc.contributor.author	Kopp, Hans-Georg
dc.date.accessioned	2020-05-28T12:51:01Z
dc.date.available	2020-05-28T12:51:01Z
dc.date.issued	2019
dc.identifier.issn	1432-1335
dc.identifier.uri	http://hdl.handle.net/10900/101056
dc.language.iso	en	en
dc.publisher	Springer	de_DE
dc.relation.uri	http://dx.doi.org/10.1007/s00432-018-2752-z
dc.subject.ddc	610	de_DE
dc.title	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190926111821_02446
utue.publikation.seiten	717-723	de_DE
utue.personen.roh	Fenner, Martin
utue.personen.roh	Oing, Christoph
utue.personen.roh	Dieing, Annette
utue.personen.roh	Gauler, Thomas
utue.personen.roh	Oechsle, Karin
utue.personen.roh	Lorch, Anja
utue.personen.roh	Hentrich, Marcus
utue.personen.roh	Kopp, Hans-Georg
utue.personen.roh	Bokemeyer, Carsten
utue.personen.roh	Honecker, Friedemann
dcterms.isPartOf.ZSTitelID	Journal of Cancer Research and Clinical Oncology	de_DE
dcterms.isPartOf.ZS-Issue	3	de_DE
dcterms.isPartOf.ZS-Volume	145	de_DE
utue.fakultaet	04 Medizinische Fakultät